Precision Biosciences (DTIL) Net Income towards Common Stockholders (2018 - 2026)
Precision Biosciences (DTIL) reported Net Income towards Common Stockholders of -$8.4 million for Q1 2026, up 60.33% year-over-year from -$5.2 million in Q1 2025, and down 164.85% on a QoQ basis from $12.9 million in Q4 2025.
Precision Biosciences (DTIL) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$8.4 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 60.33% year-over-year to -$8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.6 million (up 6.76% YoY) and the FY2025 annual result came in at $885000.0, changed N/A from the prior year.
- Net Income towards Common Stockholders retreated to -$8.4 million in Q1 2026 per DTIL's latest filing, from $12.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $25.4 million in Q2 2024 and bottomed at -$29.5 million in Q2 2022.
- The 5-year median for Net Income towards Common Stockholders is -$9.1 million (2022), against an average of -$10.1 million.
- Peak annual rise in Net Income towards Common Stockholders reached 387.07% in 2024, while the deepest fall reached 731.66% in 2024.
- Tracing DTIL's Net Income towards Common Stockholders over 5 years: stood at -$9.1 million in 2022, then jumped by 68.49% to -$2.9 million in 2023, then slumped by 731.66% to -$23.7 million in 2024, then jumped by 154.47% to $12.9 million in 2025, then slumped by 164.85% to -$8.4 million in 2026.
- Per Business Quant, the three latest DTIL Net Income towards Common Stockholders figures stand at -$8.4 million (Q1 2026), $12.9 million (Q4 2025), and -$20.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | -8.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.39 Mn |
| Dec 31, 2025 | 12.93 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Jun 30, 2025 | -21.12 Mn |
| Mar 31, 2025 | -21.14 Mn |
| Dec 31, 2024 | -23.74 Mn |
| Sep 30, 2024 | -19.77 Mn |
| Jun 30, 2024 | 25.43 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -2.86 Mn |
| Sep 30, 2023 | 4.03 Mn |
| Jun 30, 2023 | -8.86 Mn |
| Mar 31, 2023 | -11.11 Mn |
| Dec 31, 2022 | -9.06 Mn |
| Sep 30, 2022 | -8.26 Mn |
| Jun 30, 2022 | -29.54 Mn |
| Mar 31, 2022 | -27.21 Mn |
| Dec 31, 2021 | -30.71 Mn |
| Sep 30, 2021 | -11.55 Mn |
| Jun 30, 2021 | 21.66 Mn |
| Mar 31, 2021 | -18.69 Mn |
| Dec 31, 2020 | -23.45 Mn |
| Sep 30, 2020 | -26.02 Mn |
| Jun 30, 2020 | -32.70 Mn |
| Mar 31, 2020 | -26.84 Mn |
| Dec 31, 2019 | -20.92 Mn |
| Sep 30, 2019 | -20.74 Mn |
| Jun 30, 2019 | -22.39 Mn |
| Mar 31, 2019 | -19.08 Mn |
| Dec 31, 2018 | -15.44 Mn |
| Sep 30, 2018 | -9.76 Mn |
| Jun 30, 2018 | -11.83 Mn |
| Mar 31, 2018 | -9.01 Mn |